SPDR S&P Biotech ETF
406 hedge funds and large institutions have $5.44B invested in SPDR S&P Biotech ETF in 2019 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 118 increasing their positions, 136 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
23% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 65
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
54% less call options, than puts
Call options by funds: $829M | Put options by funds: $1.81B
Holders
406
Holding in Top 10
10
Calls
$829M
Puts
$1.81B
Top Buyers
| 1 | +$202M | |
| 2 | +$193M | |
| 3 | +$149M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$83.8M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$59.9M |
Top Sellers
| 1 | -$250M | |
| 2 | -$112M | |
| 3 | -$67.7M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$50.3M |
| 5 |
Two Sigma Advisers
New York
|
-$39.8M |